Calmark intensifies efforts in India

Calmark intensifies efforts in India

Press releases
Calmark Sweden AB (publ) (“Calmark” or “the Company”) announces today that it will intensify efforts in relation to the market launch in India, and that the potential is considered to be significant. The Company has supplied India with instruments and COVID19-LDH tests in view of a possible procurement.

As previously disclosed, Calmark has entered an exclusive distributor agreement with the company r2 Diagnostics in India. Several orders have been received from the distributor and delivered to the Indian market. These instruments are being evaluated ahead of a possible procurement of pandemic-related products by Indian authorities. This is managed by Calmark’s distributor. The procurement will mainly be contingent upon the assessment of how a third wave of COVID-19 would impact the country. There is no established timeline for the procurement, as this will be determined by the COVID-19 situation. Nor is it clear how Calmark’s COVID19-LDH product would fare in such a procurement, but the Company has initiated an overall ramp-up to ensure its capacity to meet demand.

In parallel, the work to register Calmark's COVID19-LDH test cassette in the Indian market is progressing. The POC-Analyzer Covid instrument has already obtained registration.

“We are enjoying an excellent cooperation with r2 Diagnostics, and they are doing extraordinarily good work on our pandemic product in the Indian market,” says Magdalena Tharaldsen, Director International Business Development at Calmark.

This information is information that Calmark Sweden AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on 18 October 2021, 16:30 CET.

Every care has been taken in the translation of this document. In the event of discrepancies, the Swedish original will supersede the English translation.